Efficacy of standard and low dose hydrochlorothiazide in the recurrence prevention of calcium nephrolithiasis (NOSTONE trial): protocol for a randomized double-blind placebo-controlled trial.

Publikation

Efficacy of standard and low dose hydrochlorothiazide in the recurrence prevention of calcium nephrolithiasis (NOSTONE trial): protocol for a randomized double-blind placebo-controlled trial.

Wissenschaftlicher Artikel/Review - 10.12.2018

Dhayat Nasser A, Faller Nicolas, Bonny Olivier, Mohebbi Nilufar, Ritter Alexander, Pellegrini Lisa, Bedino Giulia, Schönholzer Carlo, Venzin Reto M, Hüsler Carina, Koneth Irene, Del Giorno Rosaria, Gabutti Luca, Amico Patrizia, Mayr Michael, Odermatt Urs, Buchkremer Florian, Ernandez Thomas, Stoermann-Chopard Catherine, Teta Daniel, Rintelen Felix, Roumet Marie, Irincheeva Irina, Trelle Sven, Tamò Luca, Roth Beat, Vogt Bruno, Fuster Daniel G

Zitation

Dhayat N, Faller N, Bonny O, Mohebbi N, Ritter A, Pellegrini L, Bedino G, Schönholzer C, Venzin R, Hüsler C, Koneth I, Del Giorno R, Gabutti L, Amico P, Mayr M, Odermatt U, Buchkremer F, Ernandez T, Stoermann-Chopard C, Teta D, Rintelen F, Roumet M, Irincheeva I, Trelle S, Tamò L, Roth B, Vogt B, Fuster D. Efficacy of standard and low dose hydrochlorothiazide in the recurrence prevention of calcium nephrolithiasis (NOSTONE trial): protocol for a randomized double-blind placebo-controlled trial. BMC Nephrol 2018; 19:349.

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

BMC Nephrol 2018; 19

Veröffentlichungsdatum

10.12.2018

eISSN (Online)

1471-2369

Seiten

349

Kurzbeschreibung/Zielsetzung

Nephrolithiasis is a global healthcare problem with a current lifetime risk of 18.8% in men and 9.4% in women. Given the high cost of medical treatments and surgical interventions as well as the morbidity related to symptomatic stone disease, medical prophylaxis for stone recurrence is an attractive approach. Thiazide diuretics have been the cornerstone of pharmacologic metaphylaxis for more than 40 years. However, evidence for benefits and harms of thiazides in the prevention of calcium containing kidney stones in general remains unclear. In addition, the efficacy of the currently employed low dose thiazide regimens to prevent stone recurrence is not known.